Company Profile · Healthcare

Hangzhou Tigermed Consulting

300347 · Shenzhen
Exchange
Shenzhen
Country
China
IPO date
Aug 17, 2012
Employees
11,130
Current Price
¥51.9
Live · Jul 15, 2026
Fair Buy
≤ ¥27
Margin-of-safety entry
Baillie Growth Score
44/100
Weak
Intrinsic Value · Three-Tier Range Current price ¥51.9 Live · Within the fair intrinsic-value range

Composite valuation range · conservative ¥24–¥27 / fair ¥43–¥58 / optimistic ¥79–¥86. At ¥51.9, Within the fair intrinsic-value range.

Market capCN¥39.86B
Revenue (TTM)CN¥7.07B
EBITDACN¥824.11M
Profit margin10.91%
ROE4.23%
P/E (TTM)50.87
Forward P/E28.99
PEG0
EPSCN¥0.91
Dividend yield0.27%
52-week rangeCN¥35.47 – CN¥71.69

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.